Cadila Healthcare Ltd has launched 'Slimona' new generation anti-obesity drug in India. Slimono (rimonabant) is a selective CB1 Endocannabinoid (EC) receptor antagonist indicated for the treatment of obesity.

The company has launched Slimona, the new generation anti-obesity drug in India. Slimona (Rimonabant) is a selective CB1 Endocannabinoid (EC) receptor antagonist indicated for the treatment of obesity. The group is the first company to launch this revolutionary new molecule for Indian patients. This first-in-class drug has been approved for the treatment of obese patients with associated risk factors, such as type II diabetes or dyslipidemia. The drug comes in a tablet form of strength 20 mg to be consumed before breakfast once a day (administered strictly under medical advice).

The group has already begun introducing Slimona to the medical fraternity through Medical Conferences and Continuous Medical Education (CME) initiatives. The drug is priced economically at a rate of Rs 5.50 per tablet, making it economical to a wide patient group. Emphasizing this point, Ashok Bhatia, senior vice-president (BU-7), Zydus Cadila says, The price of Slimona, has been thoughtfully fixed to benefit the large patient population in all classes. We will harness the full thrust of the Zydus marketing teams to ensure that this vitally needed drug is available to doctors across the country - even in smaller cities and towns."

The introduction of Slimona will boost the group's presence in the Chronic care segment. The company currently, markets products in cardiology, diabetology and neurology segments. The group's leading brands in the chronic care segment include Aten, Atorva, Depin and Amlodac.